Tricida Inc

Change company Symbol lookup

Select an option...

TCDAQ Tricida Inc

TDY Teledyne Technologies Inc

TGS Transportadora de Gas del Sur SA

LPRO Open Lending Corp

SLGL Sol Gel Technologies Ltd

UAVS Ageagle Aerial Systems Inc

IWSY ImageWare Systems Inc

AMPX Amprius Technologies Inc

TNC Tennant Co

CVX Chevron Corp

Go

Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.